ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
First reported urinary tract infection caused by Siccibacter turicensis in an adolescent with neurogenic bladder.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Siccibacter turicensis is a rare environmental member of the Enterobacteriaceae family that has seldom been implicated in human infection. We report what is, to our knowledge, the first case of S. turicensis-associated urinary tract infection (UTI). A 17-year-old male with traumatic spinal cord injury and catheter-dependent neurogenic bladder presented with fever and dysuria three months after a motorcycle accident. Urine culture grew a Gram-negative bacillus identified as S. turicensis by MALDI-TOF mass spectrometry and confirmed by 16 S rRNA Sanger sequencing. The isolate was susceptible to ceftriaxone (MIC 0.064 mg/L), and intravenous ceftriaxone therapy produced complete clinical and microbiological resolution within seven days. This case broadens the recognized clinical spectrum of S. turicensis beyond superficial mucosal infections and underscores the importance of advanced identification methods for detecting rare environmental pathogens in vulnerable patient populations.
Indexed as
Identifiers
42696084What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.